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Edited by Frances ShannonAbstract Toll-like receptor 3 (TLR3) recognizes dsRNA
generated during viral infection and activation of TLR3 results
in induction of type I interferons (IFNs) and cellular anti-viral
response. TLR3 is associated with a TIR domain-containing
adapter protein TRIF, which activates distinct downstream
pathways leading to activation of NF-jB and ISRE sites in the
promoters of type I IFNs. We show here that A20, a NF-jB-
inducible zinc ﬁnger protein that has been demonstrated to be an
inhibitor of TNF-induced NF-jB activation and a physiological
suppressor of inﬂammatory response, potently inhibited TLR3-
and Sendai virus-mediated activation of ISRE and NF-jB and
IFN-b promoter in reporter gene assays. A20 also inhibited
TRIF-, but not its downstream signaling components TBK1-,
IKKb-, and IKKe-mediated activation of ISRE and NF-jB and
IFN-b promoter. Moreover, A20 interacted with TRIF in co-
immunoprecipitation experiments. Finally, expression of A20
could be induced at protein level by Sendai virus infection. These
data suggest that A20 targets TRIF to inhibit TLR3-mediated
induction of IFN-b transcription and functions as a feedback
negative regulator for TLR3 signaling and cellular anti-viral
response.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Recognition of speciﬁc patterns of microbial components by
Toll-like receptors (TLRs) in the body leads to activation of
innate immunity against pathogens [1–3]. TLR3 recognizes
dsRNA generated during viral infection and activation of
TLR3 results in induction of type I interferons (IFNs), in-
cluding IFN-b and IFN-a family cytokines, which are crucial
mediators of the cellular anti-viral response.
Transcriptional activation of the promoters of type I IFNs
requires coordinated activation of multiple transcriptional* Corresponding author. Fax: +1-303-398-1396.
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doi:10.1016/j.febslet.2004.08.071factors and their cooperative assembly into a transcriptional
enhancer complex in vivo. For example, the enhancer of hu-
man IFN-b gene contains a jB site recognized by NF-jB, a
site for ATF-2/c-Jun, and two ISRE (interferon-stimulated
response element) sites recognized by IRF-3 and/or IRF-7
[4,5]. It has been shown that transcriptional activation of IFN-
b gene requires coordinated and cooperative assembly of an
enhancersome that contains all of these transcriptional factors
[4,5].
Recently, major progress has been achieved on the
mechanisms of TLR3-mediated IFN-b transcriptional in-
duction. It has been shown that TRIF, a TIR domain-
containing adapter protein, is responsible for transducing
TLR3 signals to downstream eﬀectors [6–9]. TRIF activates
NF-jB through a RIP-TRAF6-IKKb dependent pathway
[6–8]. TRIF activates ISRE through TBK1-, IKKb- and
IKKe-mediated phosphorylation of IRF-3 and/or IRF-7
[6,8]. In addition, it has also been shown that TRIF can
induce apoptosis through a RIP-FADD-caspase-8 dependent
pathway [6].
Negative regulation of TLR3-mediated production of type I
IFNs is less understood. In this report, we identiﬁed A20 as a
potent inhibitor of TLR3- and Sendai virus-induced ISRE
activation and IFN-b transcription. A20 was originally iden-
tiﬁed as a TNF-inducible protein in human endothelial cells
[10]. Subsequently, it has been shown that A20 is induced by a
variety of proinﬂammatory reagents through activation of NF-
jB [11]. A20 contains seven zinc ﬁnger motifs having charac-
teristics of CX2–4CX11CX2C at its C-terminal domain [10,11].
It has been shown that A20 interacts with TRAF2, RIP, IKKc
and TRAF6, which are signaling components involved in
TNF, IL-1 and TLR-mediated NF-jB activation pathways
[12–17]. Overexpression of A20 inhibits NF-jB activation
triggered by various stimuli, including TNF, IL-1, and LPS
[10–19]. A20-deﬁcient cells fail to terminate TNF-induced NF-
jB activation [20]. Mice deﬁcient for A20 develop severe in-
ﬂammation and cachexia, are hypersensitive to both LPS and
TNF, and die prematurely [20]. These studies suggest that A20
is a physiological inhibitor of NF-jB activation and inﬂam-
matory response.
In this report, we found that A20 interacted with TRIF and
potently inhibited TLR3- and Sendai virus-induced activation
of ISRE and IFN-b promoter. Our ﬁndings suggest that A20 is
an inducible protein that blocks both inﬂammatory and cel-
lular anti-viral responses.blished by Elsevier B.V. All rights reserved.
Fig. 1. A20 inhibits Poly(I:C)- and Sendai virus-induced activation of
ISRE, NF-jB and IFN-b promoter. (A) A20 inhibits Poly(I:C)- and
Sendai virus-induced activation of ISRE. The TLR3-expressing 293-
T3Y cells (1 105) were transfected with 0.1 lg of ISRE reporter
plasmid and 1 lg of an expression plasmid for A20 (ﬁlled bars) or an
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2.1. Reagents
Recombinant human TNF and IFN-c (R&D Systems), human
embryonic kidney 293 cells and Sendai viruses (ATCC), monoclonal
antibodies against Flag and HA epitopes (Sigma), A20 (Imgenex) and
b-tubulin (Sigma) were purchased from the indicated companies. The
293 cells expressing TLR3 (293-T3Y) were provided by Drs. Kate
Fitzgerald and Tom Maniatis.
2.2. Constructs
ISRE-luciferase reporter construct was purchased from Stratagene
(La Jolla, CA). NF-jB-luciferase reporter construct (Dr. Gary
Johnson) and mammalian expression plasmid for Flag-IKKb (Dr.
David Goeddel) were provided by the indicated investigators. Hu-
man IFN-b promoter luciferase reporter construct, and mammalian
expression plasmids for Flag- or HA-tagged TRIF, TBK1 and IKKe
were previously described [6]. Mammalian expression plasmid for
Flag-tagged A20 and its deletion mutants were constructed by in-
sertion of PCR ampliﬁed human A20 or its mutant cDNAs into a
pCMV based expression vector containing a N-terminal Flag tag.
2.3. Cell transfection and reporter gene assays
293 cells (1 105) were seeded on 12-well dishes and transfected the
following day by standard calcium phosphate precipitation. For each
transfection, 0.1 lg of the tested reporter plasmid and the indicated
amounts of expression plasmids were added. Within the same experi-
ment, each transfection was performed in duplicate. Empty control
plasmid was added to ensure that each transfection receives the same
amount of total DNA. To normalize for transfection eﬃciency, 0.1 lg
of pTK-RL (Rellina Luciferase) or RSV-b-galactosidase plasmid was
added to each transfection. Fireﬂy luciferase activities were normalized
on the basis of b-galactosidase or Rellina luciferase activities.
2.4. Co-immunoprecipitation and Western blot analysis
Transfected 293 cells from each 100-mm dish were lysed in 1 ml of
lysis buﬀer (20 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton, 1 mM
EDTA, 10 lg/ml aprotinin, 10 lg/ml leupeptin, and 1 mM phenyl-
methylsulfonyl ﬂuoride). For each immunoprecipitation, 0.4 ml ali-
quot of lysate was incubated with 0.5 lg of the indicated monoclonal
antibody and 25 ll of a 1:1 slurry of GammaBind G Plus Sepharose
(Amersham Pharmacia, Piscataway, NJ) for 1 h. The Sepharose beads
were washed three times with 1 ml lysis buﬀer containing 500 mM
NaCl. The precipitates were fractionated on SDS–PAGE and
subsequent Western blot analysis was performed with the indicated
antibodies.
2.5. Sendai virus infection
293 cells (1 105) were seeded in 12-well dishes and transfected the
next day with 0.1 lg of the indicated reporter plasmid. Fourteen hours
after transfection, cells were washed with medium lacking fetal calf
serum (washing medium) and overlaid with washing medium con-
taining Sendai virus at a multiplicity of infection of 10. After incuba-
tion at 37 C for 60 min, non-adsorbed viruses were removed by
washing of the cells. Cells were then cultured in fetal calf serum-con-
taining medium for 6 h before luciferase assays were performed.empty control plasmid (open bars). Fourteen hours after transfection,
cells were treated with Poly(I:C) (25 lg/ml) or infected with Sendai
virus or left untreated for 6 h before reporter assays were performed.
(B) A20 inhibits Poly(I:C)- and Sendai virus-induced activation of NF-
jB. The experiments were done similarly as in A except that NF-jB-
luciferase reporter plasmid was used. (C) A20 inhibits Poly(I:C)- and
Sendai virus-induced activation of IFN-b promoter. The experiments
were done similarly as in A except that human IFN-b promoter lu-
ciferase reporter plasmid was used. (D) A20 inhibits TNF-induced NF-
jB activation but not IFN-c-induced IRF-1 promoter activation. 293
cells (1 105) were transfected with 0.1 g of NF-jB or IRF-1 promoter
reporter plasmid as indicated and 1 lg of an expression plasmid for
A20 (ﬁlled bars) or an empty control plasmid (open bars). Fourteen
hours after transfection, cells were treated with TNF (20 ng/ml) or
IFN-c (100 ng/ml) or left untreated for 6 h before reporter assays were
performed. SeV, Sendai virus.3. Results and discussion
3.1. A20 inhibits TLR3- and Sendai virus-induced activation of
ISRE and NF-jB and IFN-b promoter
Previously, it has been shown that A20 can inhibit NF-jB
activation induced by various stimuli, including TNF, IL-1
and TLR4 [10–19]. We examined whether A20 could also in-
hibit signaling by TLR3. To do this, we performed reporter
gene assays utilizing a TLR3-expressing stable cell line. As
shown in Fig. 1A, ectopic expression of A20 potently inhibited
ISRE activation triggered by stimulation with the TLR3 ligand
Poly(I:C). In similar experiments, A20 also inhibited Poly-
(I:C)-induced activation of NF-jB and IFN-b promoter
(Fig. 1B and C).
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fection, we determined whether A20 could inhibit Sendai virus-
induced ISRE and NF-jB activation and IFN-b transcription.
In reporter gene assays, A20 potently inhibited Sendai virus-
induced activation of ISRE, NF-jB and IFN-b promoter
(Fig. 1). In similar experiments, A20 inhibited TNF-induced
NF-jB activation, but not IFN-c-induced activation of the
IRF-1 promoter (Fig. 1D).
Taken together, these data suggest that A20 is a potent and
speciﬁc inhibitor of TLR3-mediated activation of ISRE and
NF-jB and IFN-b promoter.
3.2. A20 inhibits TRIF-, but not TBK1-, IKKb- and
IKKe-mediated activation of NF-jB, ISRE and IFN-b
promoter
It has been shown that TLR3 is associated with the TIR-
domain containing adapter protein TRIF, which in turn acti-
vates ISRE and NF-jB through distinct downstream pathways
[6,8,21–23]. To determine which component in TLR3 signaling
is targeted by A20, we determined whether A20 could inhibitFig. 2. A20 inhibits TRIF-, but not TBK1-, IKKb- and IKKe-medi-
ated activation of ISRE, NF-jB and IFN-b promoter. (A) A20 inhibits
TRIF-, but not TBK1-, IKKb- and IKKe-mediated NF-jB activation.
293 cells (1 105) were transfected with 0.1 lg of NF-jB reporter
plasmid and 0.5 lg of each of the indicated plasmid. Reporter assays
were performed 14 h after transfection. (B) A20 inhibits TRIF-, but
not TBK1-, IKKb- and IKKe-mediated ISRE activation. The experi-
ments were done similarly as in A except that ISRE-luciferase reporter
plasmid was used. (C) A20 inhibits TRIF-, but not TBK1-, IKKb- and
IKKe-mediated activation of IFN-b promoter. The experiments were
done similarly as in A except that human IFN-b promoter luciferase
reporter plasmid was used.signaling mediated by various components in TLR3 pathways.
In reporter gene assays, A20 could potently inhibit TRIF-, but
not TBK1-, IKKe- and IKKb-induced activation of ISRE,
NF-jB and IFN-b promoter (Fig. 2). These data suggest that
A20 inhibits TLR3 signaling by targeting TRIF or its up-
stream component(s).
3.3. A20 interacts with TRIF
Since A20 inhibits TLR3 signaling by targeting TRIF or its
upstream components, we determined whether A20 could in-
teract with TRIF. In transient transfection and co-immuno-
precipitation experiments, A20 could interact with TRIF
(Fig. 3A). One possible mechanism responsible for A20-med-
iated inhibition of TLR3 signaling is that A20 competes with
downstream components for interaction with TRIF. To test
this, we determined whether A20 could compete with
TRAF6 for interaction with TRIF. In co-immunoprecipitationFig. 3. A20 interacts with TRIF but does not cause downregulation of
TRIF protein level. (A) A20 interacts with TRIF. 293 cells (2 106)
were transfected with 5 lg of each of the indicated expression plasmids.
Cell lysates were immunoprecipitated with a monoclonal anti-HA
antibody. The immunoprecipitates were analyzed by Western blot with
anti-Flag antibody (upper panel). The expression levels of the trans-
fected proteins were detected by Western blot analysis with anti-Flag
(middle panel) or anti-HA (low panel) antibody. (B) A20 does not
cause downregulation of TRIF protein level. 293 cells (2 105) were
transfected with 0.5 lg of HA-TRIF plasmid, 0.5 lg of HA-TIRP
plasmid, and increased amounts of Flag-A20 plasmid as indicated.
Sixteen hours after transfection, cell lysates were analyzed by Western
blot with a mixture of anti-Flag and anti-HA antibodies.
Fig. 5. Induction of A20 expression by Sendai virus infection and TNF
stimulation. U937 cells (3 105) were treated with TNF (20 ng/ml) or
infected with Sendai virus (SeV) or left untreated for 18 h. Cells were
then lysed and the lysates were analyzed by Western blot with a
monoclonal anti-A20 antibody (upper panel). The same blot was re-
probed with a monoclonal anti-b-tubulin antibody (lower panel).
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for binding to TRIF (Fig. 3A).
3.4. A20 does not downregulate TRIF protein level
We further examined whether A20 caused downregulation
of TRIF protein level. We co-transfected 293 cells with con-
stant amounts of TRIF expression plasmid, increased amounts
of A20 expression plasmid, and constant amounts of an ex-
pression plasmid for a control protein TIRP. Western blot
analysis indicated that A20 did not signiﬁcantly aﬀect the level
of TRIF expression (Fig. 3B). These data suggest that A20-
mediated inhibition of TRIF signaling is not due to down-
regulation of TRIF expression.
3.5. A20’s de-ubiquitination activity is not required for its
inhibitory eﬀects on Sendai virus-induced ISRE activation
Recently, it has been shown that A20 is a de-ubiquitinating
enzyme [23]. However, its de-ubiquitination activity is not re-
quired for its inhibition of TNF-induced NF-jB activation
[23]. Consistent with the previous observation [23], we found
that the C-terminal zinc ﬁnger domain of A20, aa370–775,
which lacks the N-terminal de-ubiquitinating catalytic domainFig. 4. The de-ubiquitinating activity of A20 is not required for its
inhibitory eﬀects on NF-jB and ISRE activation. (A) The de-ubiqui-
tinating activity of A20 is not required for its inhibitory eﬀect on TNF-
induced NF-jB activation. 293 cells (1 105) were transfected with 0.1
lg of NF-jB reporter plasmid and 1 lg of the indicated expression
plasmids. Fourteen hours after transfection, cells were treated with
TNF (10 ng/ml) (ﬁlled bars) or left untreated (empty bars) for 6 h
before reporter assays were performed. (B) The de-ubiquitinating ac-
tivity of A20 is not required for its inhibitory eﬀect on Sendai virus-
induced ISRE activation. 293 cells (1 105) were transfected with 0.1 g
of ISRE-luciferase reporter plasmid and 1 lg of the indicated expres-
sion plasmids. Fourteen hours after transfection, cells were infected
with Sendai virus (ﬁlled bars) or left uninfected (empty bars) for 6 h
before reporter assays were performed.[23], was as eﬀective as the full-length A20 in inhibiting TNF-
induced NF-jB activation in reporter gene assays (Fig. 4A). In
these assays, the N-terminal domain of A20, aa1-369, had little
inhibitory eﬀect on TNF-induced NF-jB activation (Fig. 4A).
Similarly, A20-(aa370–775) also signiﬁcantly inhibited Sendai
virus-induced ISRE activation (Fig. 4B). These data suggest
that the de-ubiquitinating activity of A20 is not required for its
inhibitory eﬀects on NF-jB and ISRE activation by various
stimuli.
3.6. Sendai virus infection induces expression of A20 at protein
level
Previous studies have shown that A20 is a feedback negative
regulator of TNF-induced NF-jB activation and inﬂammation
[10–20]. Since A20 is a potent inhibitor of TLR3- and Sendai
virus-induced transcription of IFN-b, we wondered whether
A20 could act as a negative feedback regulator of viral infec-
tion. Therefore, we examined whether Sendai virus infection
could induce expression of A20. As shown in Fig. 5, infection
of the monocytic U937 cells with Sendai virus signiﬁcantly
induced A20 at protein level. As a positive control, TNF also
upregulated A20 in the same experiment (Fig. 5). Interestingly,
both Sendai virus infection and TNF treatment did not upre-
gulate A20 in 293 cells (data not shown). These data suggest
that both Sendai virus and TNF can upregulate A20 in a cell-
type speciﬁc manner.
The exact biochemical mechanisms responsible for A20-
mediated inhibition of TLR3 signaling need to be further
investigated. Nevertheless, our discovery of A20 as a potent
inhibitor of TLR3-induced ISRE and NF-jB activation and
IFN-b transcription provides an interesting link between in-
ﬂammatory response and innate immunity against viruses. Our
data point to the following model: viral infection leads to
upregulation of A20, which in turn inhibits virus-induced IFN
transcription and cellular anti-viral response.
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